Note
8 - Common Stock Warrants
COMMON
STOCK WARRANTS
A
summary of the Company’s warrant issuance activity and related information for the nine months ended September 30, 2021 and
2022 is as follows:
SCHEDULE
OF ISSUANCE OF WARRANTS
|
|
Shares |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Remaining Contractual Life |
|
Outstanding and exercisable at December 31, 2020 |
|
|
413,424 |
|
|
$ |
15.00 |
|
|
|
10.30 |
|
Expired |
|
|
(5,783 |
) |
|
|
33.00 |
|
|
|
— |
|
Outstanding and exercisable at September 30, 2021 |
|
|
407,641 |
|
|
|
58.00 |
|
|
|
8.42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding and exercisable at December 31, 2021 |
|
|
406,301 |
|
|
$ |
34.88 |
|
|
|
8.17 |
|
Expired |
|
|
(22,513 |
) |
|
|
373.85 |
|
|
|
— |
|
Exercised |
|
|
(83,579 |
) |
|
|
14.00 |
|
|
|
— |
|
Granted |
|
|
140,829 |
|
|
|
9.41 |
|
|
|
4.63 |
|
Outstanding and exercisable at September 30, 2022 |
|
|
441,038 |
|
|
$ |
12.52 |
|
|
|
6.84 |
|
The
fair value of all warrants issued are determined by using the Black-Scholes valuation technique. The inputs used in the Black-Scholes
valuation technique to value each of the warrants as of their respective issue dates are as follows:
SCHEDULE
OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE
Event Description |
|
Date |
|
|
Number of Warrants |
|
|
H-CYTE Stock Price |
|
|
Exercise Price of Warrant |
|
|
Grant Date Fair Value |
|
|
Life of Warrant |
|
|
Risk Free Rate of Return (%) |
|
|
Annualized Volatility Rate (%) |
|
Granted for inducement agreement |
|
|
1/19/2022 |
|
|
|
3,732 |
|
|
$ |
63.25 |
|
|
$ |
14.00 |
|
|
$ |
62.00 |
|
|
|
5 years |
|
|
|
1.62 |
|
|
|
187.79 |
|
Granted for inducement agreement |
|
|
1/20/2022 |
|
|
|
372 |
|
|
$ |
64.50 |
|
|
$ |
14.00 |
|
|
$ |
64.00 |
|
|
|
5 years |
|
|
|
1.62 |
|
|
|
187.85 |
|
Granted for inducement agreement |
|
|
1/20/2022 |
|
|
|
187 |
|
|
$ |
64.50 |
|
|
$ |
14.00 |
|
|
$ |
64.00 |
|
|
|
5 years |
|
|
|
1.62 |
|
|
|
187.85 |
|
Granted for inducement agreement |
|
|
1/24/2022 |
|
|
|
374 |
|
|
$ |
48.00 |
|
|
$ |
14.00 |
|
|
$ |
47.00 |
|
|
|
5 years |
|
|
|
1.53 |
|
|
|
188.01 |
|
Granted for inducement agreement |
|
|
1/25/2022 |
|
|
|
3,744 |
|
|
$ |
49.10 |
|
|
$ |
14.00 |
|
|
$ |
48.00 |
|
|
|
5 years |
|
|
|
1.56 |
|
|
|
188.00 |
|
Granted for inducement agreement |
|
|
2/02/2022 |
|
|
|
3,741 |
|
|
$ |
44.55 |
|
|
$ |
14.00 |
|
|
$ |
44.00 |
|
|
|
5 years |
|
|
|
1.60 |
|
|
|
188.25 |
|
Granted for inducement agreement |
|
|
2/04/2022 |
|
|
|
6,935 |
|
|
$ |
44.38 |
|
|
$ |
14.00 |
|
|
$ |
43.00 |
|
|
|
5 years |
|
|
|
1.78 |
|
|
|
188.33 |
|
Granted for inducement agreement |
|
|
2/04/2022 |
|
|
|
13,870 |
|
|
$ |
44.38 |
|
|
$ |
14.00 |
|
|
$ |
43.00 |
|
|
|
5 years |
|
|
|
1.78 |
|
|
|
188.33 |
|
Granted for services provided |
|
|
2/09/2022 |
|
|
|
1,000 |
|
|
$ |
32.00 |
|
|
$ |
14.00 |
|
|
$ |
31.00 |
|
|
|
5 years |
|
|
|
1.82 |
|
|
|
188.69 |
|
Granted for inducement agreement |
|
|
2/22/2022 |
|
|
|
41,609 |
|
|
$ |
32.88 |
|
|
$ |
14.00 |
|
|
$ |
32.00 |
|
|
|
5 years |
|
|
|
1.85 |
|
|
|
188.59 |
|
Granted for inducement agreement |
|
|
2/22/2022 |
|
|
|
693 |
|
|
$ |
32.88 |
|
|
$ |
14.00 |
|
|
$ |
32.00 |
|
|
|
5 years |
|
|
|
1.85 |
|
|
|
188.59 |
|
Granted for inducement agreement |
|
|
3/21/2022 |
|
|
|
8,322 |
|
|
$ |
28.00 |
|
|
$ |
14.00 |
|
|
$ |
27.00 |
|
|
|
5 years |
|
|
|
2.33 |
|
|
|
194.01 |
|
Granted for securities purchase agreement |
|
|
9/27/2022 |
|
|
|
56,250 |
|
|
$ |
6.00 |
|
|
$ |
2.50 |
|
|
$ |
5.94 |
|
|
|
5 years |
|
|
|
4.21 |
|
|
|
213.54 |
|
The
fair value of warrants issued during the three and nine months ended September 30, 2022 totaled approximately $334,000 and
is included in warrant expense. The fair value of warrants issued as a result of the warrant inducement during the three and nine
months ended September 30, 2022 totaled approximately $0
and $3,024,000,
respectively, and is included in inducement expense. The methods described above may produce a fair value calculation that may not be indicative of
net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are
appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair
value of certain financial instruments could result in a different fair value measurement at the reporting date.
|